FTC Wins $448M Ruling Against AbbVie For Sham Litigation Rather Than Pay-For-Delay Deal
Court finds AbbVie used sham litigation to maintain its monopoly on AndroGel but denies FTC request for an injunction; it is the largest monetary award in a litigated FTC antitrust case.
You may also be interested in...
A joint meeting of the US FDA and the FTC on biosimilar competition may have delivered a symbolic message about the need for a ‘level playing field’ in the biologics market – but it did not deliver much in the way of an actionable agenda for antitrust regulators.
Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.
US FDA is talking tough on antitrust enforcement. But is there any reason to think FTC is listening?